oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Age but not Philadelphia positivity impairs outcome in older/elderly patients with Acute Lymphoblastic Leukemia in the Swedish population
Örebro University, School of Health Sciences. Hematology Section, Department of Medicine.ORCID iD: 0000-0002-0283-4418
Hematology, Department of Medical Sciences, Uppsala University, Uppsala.
Department of Hematology, University Hospital of Linköping, Linköping.
Division of Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm.
Show others and affiliations
(English)Manuscript (preprint) (Other academic)
National Category
General Practice
Identifiers
URN: urn:nbn:se:oru:diva-48533OAI: oai:DiVA.org:oru-48533DiVA, id: diva2:905866
Available from: 2016-02-23 Created: 2016-02-23 Last updated: 2018-01-10Bibliographically approved
In thesis
1. Prognostic factors, treatment and outcome in adult acute lymphoblastic leukemia: Population-based studies in Sweden
Open this publication in new window or tab >>Prognostic factors, treatment and outcome in adult acute lymphoblastic leukemia: Population-based studies in Sweden
2016 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Acute lymphoblastic leukemia (ALL) has poor prognosis in older/elderly adults and in high-risk/relapsed disease. Recommended treatment of ALL was evaluated (study I-IV). Data was obtained from the Swedish Acute Leukemia registries and from patient records.

I. We assessed ALL relapse treatment and outcome in 76 patients aged 15-65 years (y). Complete remission (CR) was achieved in 50/71 patients (70%). Of them, 29 underwent allogeneic hematopoietic stem cell transplantation (hSCT). Five year overall survival (OS) was 15%, but close to 50% in 19 patients <35y after hSCT.

II. We studied outcome of treatment with the Hyper-CVAD protocol in 19 of 24 patients with T-ALL aged 18-72y. CR was reached in 89%, but 5y leukemia-free survival was only 29%, and 20% in 15 patients not transplanted in CR1. Six patients received hSCT in CR2. Finally, 5y OS in all 19 patients was 47%. The only negative prognostic factor found was age ≥35y.

III. We evaluated minimal residual disease (MRD) monitoring in 35 patients with Philadelphia (Ph) negative B-ALL aged 46-79y and treated with the ABCDV protocol. The CR rate was 91%. MRD was measured by flow cytometry in 73% in CR1 (MRD1) and omitted in those >70y or with high-risk ALL. Five patients received hSCT (only one due to MRD). Five year OS in the whole cohort was 47%. Continuous CR but not OS was improved in patients with MRD1 <0.1 %.

IV. We studied 155 patients with ALL (Ph+ in 35%) aged 55-85y and treated with remission induction/palliation (124/31). Both, intensive, and palliative treatment resulted in the CR rates of 70/83/16% and 3y OS of 26/32/3%. OS was negatively influenced by age and platelet count ≤35×109/L (but not Ph+). OS was not enhanced by introduction of an age-adapted protocol.

We concluded that intensive treatment with subsequent allogeneic hSCT is the most reasonable option in younger patients with ALL recurrence (I). Hyper-CVAD has low relapse-preventing efficacy (II). MRD guided intensification is probably feasible in only a minority of older patients (III). Prognosis in elderly ALL is poor, but no longer impaired by Ph+ (IV).

Place, publisher, year, edition, pages
Örebro: Örebro university, 2016. p. 56
Series
Örebro Studies in Medicine, ISSN 1652-4063 ; 134
Keywords
Acute Lymphoblastic Leukemia, adult, chemotherapy, prognosis, population-based
National Category
Cancer and Oncology Hematology General Practice
Research subject
Oncology
Identifiers
urn:nbn:se:oru:diva-47424 (URN)978-91-7529-121-5 (ISBN)
Public defence
2016-03-18, Universitetssjukhuset, hörsal C2, Södra Grev Rosengatan, Örebro, 13:00 (English)
Opponent
Supervisors
Available from: 2016-01-15 Created: 2016-01-15 Last updated: 2018-01-10Bibliographically approved

Open Access in DiVA

No full text in DiVA

Authority records BETA

Kozlowski, PiotrÅström, Maria

Search in DiVA

By author/editor
Kozlowski, PiotrÅström, Maria
By organisation
School of Health Sciences
General Practice

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 566 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf